Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Trinity Biotech plc is a diagnostics & research business based in the US. Trinity Biotech shares (TRIB) are listed on the NASDAQ and all prices are listed in US Dollars. Trinity Biotech employs 477 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $1.30 |
|---|---|
| 52-week range | $0.86 - $3.05 |
| 50-day moving average | $1.26 |
| 200-day moving average | $1.47 |
| Wall St. target price | $4.00 |
| PE ratio | 33 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.3 from 2022-07-06
| 1 week (2022-06-30) | 5.69% |
|---|---|
| 1 month (2022-06-07) | -5.80% |
| 3 months (2022-04-07) | 30.00% |
| 6 months (2022-01-07) | -0.76% |
| 1 year (2021-07-07) | -49.22% |
|---|---|
| 2 years (2020-07-07) | -48.82% |
| 3 years (2019-07-05) | 1.7 |
| 5 years (2017-07-07) | 5.7 |
Valuing Trinity Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trinity Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Trinity Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Trinity Biotech shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Trinity Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Trinity Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Trinity Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.7 million.
The EBITDA is a measure of a Trinity Biotech's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $86.1 million |
|---|---|
| Operating margin TTM | 6.96% |
| Gross profit TTM | $38.1 million |
| Return on assets TTM | 3.1% |
| Return on equity TTM | -190.56% |
| Profit margin | -15.1% |
| Book value | $0.04 |
| Market capitalisation | $50.3 million |
TTM: trailing 12 months
We're not expecting Trinity Biotech to pay a dividend over the next 12 months.
Trinity Biotech's shares were split on a 1:4 basis on 1 June 2005. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trinity Biotech shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Trinity Biotech shares which in turn could have impacted Trinity Biotech's share price.
Over the last 12 months, Trinity Biotech's shares have ranged in value from as little as $0.86 up to $3.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trinity Biotech's is 1.3203. This would suggest that Trinity Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.